In the present study, we aimed to evaluate the expression levels of PD-L1 and MET as two potential therapeutic targets using IHC analysis of SCLC specimens and to further explore their clinical relevance and prognostic role in this aggressive malignancy. The gene discussed is MET; the disease is small cell lung carcinoma.